Central Nervous System Neoplasms
"Central Nervous System Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
| Descriptor ID |
D016543
|
| MeSH Number(s) |
C04.588.614.250 C10.551.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Neoplasms".
This graph shows the total number of publications written about "Central Nervous System Neoplasms" by people in this website by year, and whether "Central Nervous System Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 4 | 1 | 5 |
| 2008 | 3 | 1 | 4 |
| 2009 | 4 | 1 | 5 |
| 2010 | 7 | 0 | 7 |
| 2011 | 2 | 1 | 3 |
| 2013 | 3 | 0 | 3 |
| 2014 | 5 | 0 | 5 |
| 2015 | 4 | 0 | 4 |
| 2016 | 5 | 2 | 7 |
| 2017 | 10 | 0 | 10 |
| 2018 | 5 | 1 | 6 |
| 2019 | 8 | 1 | 9 |
| 2020 | 5 | 0 | 5 |
| 2021 | 8 | 0 | 8 |
| 2022 | 5 | 0 | 5 |
| 2023 | 8 | 0 | 8 |
| 2024 | 5 | 0 | 5 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Neoplasms" by people in Profiles.
-
Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer. J Natl Cancer Inst. 2025 May 01; 117(5):1036-1045.
-
Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. Clin Cancer Res. 2025 May 01; 31(9):1587-1595.
-
Update on Cancer and Central Nervous System Tumor Surveillance in Pediatric NF2-, SMARCB1-, and LZTR1-Related Schwannomatosis. Clin Cancer Res. 2025 Apr 14; 31(8):1400-1406.
-
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv. 2025 Mar 11; 9(5):1171-1180.
-
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review. JAMA Oncol. 2025 Mar 01; 11(3):317-328.
-
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
-
Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2025 Apr; 25(4):271-284.
-
Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors. J Hematop. 2024 Dec; 17(4):215-222.
-
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4856-4865.
-
A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. Cancer Med. 2024 Nov; 13(21):e70376.